| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | PDPK1; PDK1; 3-phosphoinositide-dependent protein kinase 1; hPDK1 |
| Entrez GeneID | 5170 |
| WB Predicted band size | Calculated MW: 63 kDa; Observed MW: 63 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | A synthetic peptide of human PDPK1 |
| Formulation | Purified antibody in TBS with 0.05% sodium azide,0.05%BSA and 50% glycerol. |
+ +
以下是3-4篇与PDPK1(PDK1)抗体相关的参考文献，涵盖其在不同研究中的应用：
1. **"Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Bα"**
- **作者**: Alessi, D.R. et al.
- **摘要**: 该研究首次鉴定了PDPK1作为Akt激酶的激活因子，通过特异性抗体证实了PDPK1在细胞中的表达，并阐明了其在胰岛素信号通路中对Akt的磷酸化作用。
2. **"Impaired glucose homeostasis in mice lacking the kinase PDK1 in skeletal muscle"**
- **作者**: Bayascas, J.R. et al.
- **摘要**: 研究利用PDK1条件性敲除小鼠模型，通过Western blot和免疫组化(使用PDK1抗体)证明骨骼肌中PDK1缺失导致葡萄糖代谢异常，强调了PDK1在能量稳态中的关键作用。
3. **"The role of PDK1 in cancer progression and therapeutic targeting"**
- **作者**: Pearce, L.R. et al.
- **摘要**: 综述了PDK1在肿瘤发生中的功能，并引用多项实验(如免疫沉淀和磷酸化分析)，强调了PDK1抗体在检测其表达及活性调控中的应用，为靶向治疗提供依据。
4. **"Regulation of mTOR complex 1 by PDK1-mediated phosphorylation of mTOR-Ser1412"**
- **作者**: Sato, T. et al.
- **摘要**: 研究发现PDK1通过磷酸化mTOR调控其活性，实验中使用PDK1抗体进行共免疫沉淀和功能缺失分析，揭示了PDK1-mTOR轴在细胞生长中的新机制。
这些文献展示了PDK1抗体在机制研究、疾病模型及靶点探索中的广泛应用。
The 3-phosphoinositide-dependent protein kinase-1 (PDPK1), also known as PDK1. is a serine/threonine kinase that plays a central role in regulating cell survival, proliferation, and metabolism. It acts as a master regulator of the AGC kinase family (including Akt/PKB, SGK, and PKC), which are critical for signaling pathways such as PI3K/AKT/mTOR. PDPK1 phosphorylates these downstream kinases at their activation loops, enabling their full enzymatic activity. Dysregulation of PDPK1 is implicated in cancer, diabetes, and neurodegenerative disorders, making it a therapeutic target and a focus of biomarker research.
PDPK1 antibodies are essential tools for studying its expression, localization, and interactions in normal and diseased tissues. They are widely used in techniques like Western blotting, immunohistochemistry (IHC), immunoprecipitation (IP), and flow cytometry. These antibodies typically target specific epitopes, such as the N-terminal kinase domain or C-terminal PH domain of PDPK1. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple isoforms. Validation via knockout cell lines, siRNA knockdown, or recombinant protein controls is critical to confirm antibody specificity. Commercially available PDPK1 antibodies are also used in drug development to assess PDPK1 inhibition efficacy. Due to its role in oncogenic signaling, PDPK1-targeting antibodies and inhibitors are being explored for cancer therapy, particularly in tumors with PI3K/AKT pathway activation.
×
